We read with great interest the recent paper of Sekine et al. [1] , who analyzed in detail the quality of life and disease-related symptoms in previously treated patients with non-small-cell lung cancer (NSCLC) (V-15-32 trial), and the editorial of William et al. [2] , who reanalyzed the role of second-line treatments in advanced NSCLC. In the last years, the treatment options for advanced, previously treated NSCLC changed, and at present, every-3-weeks docetaxel, weekly docetaxel, pemetrexed, or epidermal growth factor receptor inhibitors (erlotinib and gefitinib) represent the main options. However, despite the interesting data emerging from the trials supporting the use of these novel options, on the whole, the final results of all these trials remain discouraging and the improvement in overall survival or progression-free interval in unselected patients is quite modest [3] . None the less, the data about the quality of life investigated as secondary end point in two phase III randomized trials that compared every-3-weeks docetaxel with gefitinib (the V-15-32 trial [1, 4] and the INTEREST trial [5] ) indicate the possibility to review the outcomes of secondline treatments in NSCLC focusing on quality of life and symptom control. As only minor clinical and methodological heterogeneities exist between these trials (docetaxel dosage, racial prevalences, statistical power of the trials), we could carry out a pooled analysis of the most significant data using a random-effect model to assess either the number-needed-totreat (NNT) or the number-needed-to-harm (NNH) for the main outcomes. On the basis of the data reported in the two trials, the pooled odds ratios for 1-year survival rate and quality of life (assessed with the FACT-L questionnaire) were 1.049 letters to the editor Annals of Oncology [95% confidence interval (CI) 0.868-1.267] and 0.517 (95% CI 0.411-0.651), respectively. As concerns the main side-effects, the pooled odds ratios were 44.161 (95% CI 22.576-86.381) for grade III-IV neutropenia, 9.291 (95% CI 4.895-17.637) for febrile neutropenia, 2.244 (95% CI 1.462-3.443) for grade III-IV fatigue, 2.411 (95% CI 1.029-5.65) for grade III-IV nausea, 1.466 (95% CI 0.556-3.863) for grade III-IV vomiting, 0.33 (95% CI 0.121-0.903) for rash/acne, 0.925 (95% CI 0.344-2.486) for grade III-IV diarrhea, 1.126 (95% CI 0.427-2.968) for weight loss, and 7.653 (95% CI 0.963-62.534) for fluid retention. Analyzing these data in terms of NNT and NNH, we obtained an NNT = 100 in favor of docetaxel for 1-year survival rate (not statistically significant), NNT = 9 in favor of gefitinib for quality of life assessed with the FACT-L questionnaire (P < 0.001), NNH = 2 against docetaxel for neutropenia (P < 0.001), NNH = 12 against docetaxel for febrile neutropenia (P < 0.001), NNH = 31 against docetaxel for fatigue (P = 0.009), NNH = 100 against docetaxel for nausea (P = 0.033), NNT = 142 against docetaxel for fluid retention (P = 0.019), NNH = 500 against gefitinib for diarrhea (not statistically significant), NNH = 142 against gefitinib for rash/acne (not statistically significant), NNH = 200 against docetaxel for vomiting (not statistically significant), and NNH = 142 against docetaxel for weight loss (not statistically significant) (Table 1) .
In our opinion, these data are very interesting for clinical practice. The results of second-line treatments for advanced NSCLC, although interesting from a speculative point of view, remain modest for clinical practice because of the minimal improvement in overall survival and time to progression in unselected patients. The identification of quality of life as an outcome of second-line treatments of NSCLC may be of some interest for an approach mainly aimed at palliation. In this regard, the low, statistically significant NNT for quality of life, the interesting safety profile of the NNH, and the favorable NNH/NNT ratio for gefitinib in comparison with docetaxel are likely to represent new evidence to prefer gefitinib to docetaxel in daily clinical practice. We think that these data and those about the need of a selection of the patients to be treated with gefitinib on the basis of their clinical and biological characteristics [6] 
